CTOs on the Move


 
Health for health. This describes Zilis. We are building the world`s finest health and wellness brand. Our expert team` headed by Derrick DeSilva` M.D.` brings the latest science to our Ambassadors and customers. We are also founded on the belief that all children deserve adequate nutrition. With every sale` we provide life saving nutrition to children in developing countries.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.zilis.com
  • 415 US Highway 377 Street 2020
    Argyle, TX USA 76226
  • Phone: 214.705.3702

Executives

Name Title Contact Details

Similar Companies

Novel Home Healthcare Agency

Novel Home Healthcare Agency is a Dallas, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Valley Research

Valley Research is a South Bend, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

HealthPresence

HealthPresence is a Van Nuys, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Network Foundations

Network Foundations is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Blueprint Medicines

Blueprint Medicines is developing a new generation of highly selective and potent kinase therapies to dramatically improve the lives of patients with genomically defined diseases. Our approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Our ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets. We are boldly advancing a deep pipeline of highly targeted therapies against previously unaddressed drivers of disease. By focusing on genomically defined subsets of patients, we believe we can identify the people most likely to respond to our therapies, resulting in a more efficient clinical development path with a greater likelihood of success and better outcomes for patients. We see a substantial opportunity in kinase drug discovery and development to deliver breakthrough medicines that allow patients to live longer with better quality of life and prevent recurrences of disease. Kinases are involved in many hallmarks of tumor biology and are proven cancer drug targets. Currently approved drugs focus on less than 5 percent of known kinases, and the function of most kinases is unknown. Led by a team of industry innovators with a track record of bringing life-changing drugs to market, we believe Blueprint Medicines has the experience and expertise to deliver on the tremendous untapped potential of kinase therapies to improve patients’ lives. We don’t think in small steps. We think in giant leaps. We are driven by the pursuit of new ideas, new innovations, and new ways of thinking.